Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population

被引:27
|
作者
Kamat, Siddhesh A. [3 ]
Rajagopalan, Krithika [1 ]
Pethick, Ned [1 ]
Willey, Vincent [2 ,3 ]
Bullano, Michael [1 ,3 ]
Hassan, Mariam [1 ]
机构
[1] AstraZeneca Pharmaceut LP, Wilmington, DE USA
[2] Univ Sci Philadelphia, Philadelphia, PA USA
[3] HealthCore, Wilmington, DE USA
来源
JOURNAL OF MANAGED CARE PHARMACY | 2008年 / 14卷 / 07期
关键词
D O I
10.18553/jmcp.2008.14.7.632
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
BACKGROUND: Patients with bipolar disorder typically present to physicians in the depressed rather than the manic or hypomanic phase of illness. Because the depressive episodes in bipolar disorder may be indistinguishable from those in major depressive disorder (MOD), misdiagnosis may occur. OBJECTIVES: To estimate from administrative claims data and a telephone survey the prevalence of potential misdiagnosis of bipolar disorder among patients with MOD and the humanistic (health-related quality of life [HRQOL] and disability) effects associated with misdiagnosis in a managed care setting. METHODS: Administrative claims data were used to identify patients with medical claims for MOD from a database of 9 million members of commercial health plans from 3 U.S. regions. The inclusion criteria were as follows: (a) adults aged 18 years or older; (b) at least 2 medical claims, including a primary or secondary diagnosis of MOD: ICD-9-CM codes 296.2x (MOD, single episode), 296.3x (MOD, recurrent episode), or 311 (depressive disorder, not classified elsewhere) during an identification period from January 1, 2000, through March 31, 2004 (study intake period); (c) at least 12 months of pre-index and 12 months of post-index plan eligibility; and (d) active enrollment through March 31, 2005. The index date was defined as the date of the first claim for MDD during the identification period. Patients with ICD-9-CM codes for bipolar disorder at any time throughout the study period (January 1, 2000, through March 31, 2005) were excluded from this cohort. This cohort was targeted for a telephone survey that was conducted from August 1 through October 30, 2006. From the telephone survey sampling frame of 5,777, a total of 1,360 interviews were completed for a response rate of 23.5%. Respondents were screened for potential bipolar disorder using the Mood Disorder Questionnaire (MOO). The Medical Outcomes 12-Item Short Form Survey (SF-12), Version 2, a widely used and validated instrument that assesses health-related functioning, and the Sheehan Disability Scale (SDS), which measures depression-related disability, were administered to a convenience subsample of 112 survey respondents to collect HRQOL and disability information, respectively. RESULTS: Of 1,360 adult patients aged 18 years or older with a diagnosis of MDD but without a medical claim for diagnosis of bipolar disorder, 94 (6.9%) screened positive for bipolar disorder on the MDQ. More patients with a positive screen for bipolar disorder reported lifetime histories of obsessive compulsive disorder (24.5% vs. 8.2%, P<0.001), psychotic disorders or hallucinations (9.6% vs. 2.4%, P<0.001), suicidal ideation (61.7% vs. 29.4%, P< 0.001), and drug abuse (34.0% vs. 11.1 %, P< 0.001) than did patients with a negative screen for bipolar disorder. In the subgroup of patients who completed the SF-12 and SDS, patients with a positive screen for bipolar disorder (n = 33) had lower scores (i.e., greater impairment) on the social functioning, role emotional, and overall mental component summary scales of the SF-12 than did patients with a negative screen for bipolar disorder (n = 79, P<0.001), but did not significantly differ on the physical component summary scale. Patients with a positive screen for bipolar disorder on the MDQ were more likely than patients who screened MDQ-negative to report severe depression-related impairment (scores of 7 and higher on the SDS scale) with work life (54.5% vs. 24.1%, respectively, P = 0.002), social life (66.7% vs. 39.2%, P = 0.008), and family life (66.7% vs. 34.2%, P = 0.002) on the SDS. CONCLUSIONS: In this study of patients carrying medical claims for a diagnosis of MDD in their administrative claims data, approximately 7% screened positive for bipolar disorder on a validated self-report assessment instrument. Patients with MDD who screened positive for bipolar disorder reported poorer HRQOL and disability scores than did patients with MDD who screened MDQ-negative. These findings may encourage interventions for appropriate screening, diagnosis, and management of potentially misdiagnosed bipolar disorder patients.
引用
收藏
页码:632 / 642
页数:11
相关论文
共 50 条
  • [41] Microstructural Differences in the Corpus Callosum in Patients With Bipolar Disorder and Major Depressive Disorder
    Matsuoka, Kiwamu
    Yasuno, Fumihiko
    Kishimoto, Toshifumi
    Yamamoto, Akihide
    Kiuchi, Kuniaki
    Kosaka, Jun
    Nagatsuka, Kazuyuki
    Iida, Hidehiro
    Kudo, Takashi
    JOURNAL OF CLINICAL PSYCHIATRY, 2017, 78 (01) : 99 - 104
  • [42] Does anxiety increase impulsivity in patients with bipolar disorder or major depressive disorder?
    Bellani, Marcella
    Hatch, John P.
    Nicoletti, Mark A.
    Ertola, Astrid E.
    Zunta-Soares, Giovana
    Swann, Alan C.
    Brambilla, Paolo
    Soares, Jair C.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2012, 46 (05) : 616 - 621
  • [43] Quality of life in euthymic patients with unipolar major depressive disorder and bipolar disorder
    Bo, Qijing
    Tian, Lu
    Li, Feng
    Mao, Zhen
    Wang, Zhimin
    Ma, Xin
    Wang, Chuanyue
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1649 - 1657
  • [44] Optical coherence tomography angiography in patients with bipolar disorder and major depressive disorder
    Zinchuk, Mikhail
    Popova, Sofya
    Guekht, Alla
    Shpak, Alexander
    JOURNAL OF AFFECTIVE DISORDERS, 2024, 361 : 409 - 414
  • [45] The dex/CRH test and the DST in patients with bipolar disorder and major depressive disorder
    Watson, Stuart
    Gallagher, Peter
    Smith, Margaret S.
    Ferrier, I. Nicol
    Young, Allan H.
    PSYCHONEUROENDOCRINOLOGY, 2007, 32 (01) : 92 - 94
  • [46] Prevalence of diabetes in patients with major depressive disorder: a population-based study
    Chien, I-Chia
    Wu, En-Liang
    Lin, Ching-Heng
    Chou, Yiing-Jenq
    Chou, Pesus
    COMPREHENSIVE PSYCHIATRY, 2012, 53 (05) : 569 - 575
  • [47] The prevalence and impact of major depressive disorder among Chinese, Malays and Indians in an Asian multi-racial population
    Chong, Siow Ann
    Vaingankar, Janhavi
    Abdin, Edimansyah
    Subramaniam, Mythily
    JOURNAL OF AFFECTIVE DISORDERS, 2012, 138 (1-2) : 128 - 136
  • [48] The impact of migraine on patients with major depressive disorder
    Hung, CI
    Liu, CY
    Juang, YY
    Wang, SJ
    HEADACHE, 2006, 46 (03): : 469 - 477
  • [49] THE POTENTIAL MICROBIOTA BIOMARKER AND FUNCTIONAL CHARACTERISTICS BETWEEN PATIENTS WITH MAJOR DEPRESSIVE DISORDER, BIPOLAR DISORDER, AND HEALTHY CONTROLS
    Lin, Shih-Kai
    Chen, Hsi-Chung
    Chen, Chun-Hsin
    Chung, Yu-Chu
    Chen, I-Ming
    Lu, Mong-Liang
    Hsu, Cheng-Dien
    Chiu, Yi-Hang
    Wang, Tsung-Yang
    Chen, Hui-Mei
    Liu, Chih-Min
    Huang, Ming-Chyi
    Kuo, Po-Hsiu
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2023, 75 : S81 - S81
  • [50] The prevalence of major depressive disorder and bipolar disorder in freshmen assessed by self reported screening test
    Min, K. J.
    Bahk, W. M.
    Shin, Y. C.
    Yoon, B. H.
    Jon, D. I.
    Song, J. H.
    Hur, E. H.
    Choi, B. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S382 - S382